Genital herpes simplex virus infection in the adolescent: special considerations for management

An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1

This paper describes a single site, open-label Phase I clinical trial evaluating the safety, tolerability and immunogenicity in healthy volunteers of a herpes simplex polynucleotide vaccine that has previously been shown to enhance immunogenicity and protect against lethal herpes simplex virus type 2 (HSV-2) challenge in mice. Five escalating doses of the vaccine, COR-1, were given by intradermal injection to HSV-1 and 2 seronegative healthy individuals. COR-1 was found to be safe and well-tolerated; the only vaccine-related adverse events were mild. While vaccine-induced antibody responses were not detectable, cell-mediated immune responses to HSV-specific peptide groups were identified in 19 of the 20 subjects who completed the study, and local inflammation at the immunisation site was observed. This study indicates COR-1 has potential to be used as a therapeutic vaccine for HSV-2 infection.

[Serological response to herpes simplex virus type 1 and 2 infection among women of reproductive age]

INTRODUCTION

Herpes simplex viruses type 1 and 2 (HSV-1 and HSV-2) are alpha herpes viruses. Humans are the only natural host and they can be transmitted through oral or genital secretions. These viruses are ubiquitous all over the world, with different percentage rates. The aims of this paper were to determine the serological response to HSV-1 and HSV-2 infection among pregnant women and women of reproductive age and seroprevalence of HSV-1 and HSV-2 antibodies among pregnant women and women of reproductive age.

MATERIAL AND METHODS

A total of 81 serum samples were analyzed. 32 sera were collected from pregnant women, and 49 sera were from non-pregnant women of reproductive age. Serum samples were tested for IgM antibodies to both herpes simplex viruses by use of immunoenzymatic assay (Bioelisa HSV IgM Immunocapture; Biokit, Spain)). Sero-type specific ELISA tests: Bioelisa HSV-1 IgG and Bioelisa HSV-2 IgG (Biokit, Spain) were used for detection of IgG antibodies to HSV-1 and HSV-2, respectively.

RESULTS

Type-common IgM antibodies were found in 6.25% of pregnant women, and in 4.08% of women of reproductive age. Type-specific IgG antibodies to HSV-1 were detected in 68.75% of pregnant women, and in 81.63% of non-pregnant women. The seroprevalence of HSV-1 in our sample was 76.5%. Type-specific IgG antibodies to HSV-2 were detected in 12.5% of pregnant women, and in 12.24% of non-pregnant women of reproductive age. The seroprevalence of HSV-2 in the whole sample was 12.35%.

CONCLUSION

Most women have antibodies to HSV-1, which is partially protective against HSV-2 infection. The seroprevalence of HSV-2 in our sample is relatively low, and similar to seroprevalence in developed European countries. However, there is a high risk of acquiring primary genital HSV infection during pregnancy. Our sample was small, therefore further investigations are required for valid evaluation of seroprevalence of HSV-1 and HSV-2 in Serbia.

Genital herpes in adolescents

Herpes simplex virus (HSV) infections occur commonly among adolescents. Most HSV-2 infections are genital, but genital herpes can be caused by either HSV-1 or HSV-2. Weighted means were calculated based on published seroprevalence data on adolescents from the United States and found HSV-1 rates of 53.1 percent for adolescent males and 49.4 percent for adolescent females. The weighted means for HSV-2 was 15 percent for adolescent females and 12 percent for adolescent males. Most individuals who are infected with HSV-2 are unaware of their infection. Healthcare providers of adolescents should consider genital herpes even when an adolescent presents with nonspecific genital symptoms. In this article, we review current recommendations for diagnosis and management and review the psychological sequelae that can be associated with having genital herpes. Finally, we discuss biomedical interventions that are being developed to help reduce the epidemic of HSV and the challenges that these interventions face with regard to implementation.